The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
Marijuana addiction is associated with significant withdrawal symptoms, including anxiety, irritability, bodily discomfort, and insomnia. The purpose of this study is to determine the effectiveness of dronabinol in reducing withdrawal symptoms. During this twelve-week, double-blind, placebo-controlled study, study visits will occur twice each week. During study visits, participants will receive either placebo or medication. Throughout the study, all participants will receive individualized psychotherapy sessions. At each study visit, vital signs, self-report ratings, and urine samples will be collected. Participants will have a follow-up evaluation at month 6.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
156
Dronabinol
placebo
Research Foundation for Mental Hygiene, Inc.
New York, New York, United States
Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial
Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial.
Time frame: weeks 7 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.